by FDA for
Prostate Cancer Patients Before Chemo
FDA Approves Today
The drug Xtandi (enzalutamide) was FDA approved in 2012 for use in metastatic Castrate Resistant (or Hormone Refractory) prostate cancer patients AFTER they had been treated with chemotherapy. But today, the FDA approved its use in these same patients BEFORE they have had chemo, creating one more important option for these men.
Read Press Release Here.
Xtandi is a second line hormonal therapy, which can suppress testosterone at 3 different sources, giving many men an additional cancer response after failing initial hormone therapy.
Read more about Xtandi in this PCRInsights article by Dr Neal Shore -
XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer
Read more from Dr Mark Scholz's Feb 2014 blog -
Xtandi (enzalutamide), the Star of the 10th Annual Genitourinary Meeting
Also, Watch Dr Charles 'Snuffy' Myers' short videos on Xtandi -
Xtandi + Phase 3 Prevail Trial
Xtandi + PCa Remissions
For discussion with your physician(s), make sure you have a basic understanding of your personal cancer status. A researched question is a better question:
1) Are you "Castrate Resistant" (or Hormone Refractory)?
2) Do you have "Metastatsis"?
For more assistance, contact the PCRI Helpline at Help@PCRI.org